Copyright
©2014 Baishideng Publishing Group Inc.
World J Clin Oncol. Oct 10, 2014; 5(4): 730-743
Published online Oct 10, 2014. doi: 10.5306/wjco.v5.i4.730
Published online Oct 10, 2014. doi: 10.5306/wjco.v5.i4.730
Table 1 miRNAs involved in chemotherapy response regulation in breast cancer
miRNA | Drug | Target(s) | Ref. |
miR-328 | Mitoxantrone | BRCP/ABCG2 | [75] |
miR-21 | Doxorubicin | MDR1, PDCD4 | [81] |
miR-451 | Doxorubicin | MDR1 | [76] |
miR-130/107 | Cisplatin | RAD51D | [125] |
miR-345 | Cisplatin | MDR1 | [77] |
miR-326 | VP16/Doxorubicin | MRP1 | [78] |
miR-128 | Doxorubicin | BMI1, ABCC5 | [79] |
miR-34a | Docetaxel | BCL-2, CCND1 | [83] |
miR-125b | Doxorubicin | BAK1 | [84] |
Paclitaxel | E2F3 | [85] | |
miR-200b/c | Doxorubicin | ZEB1, PTEN | [86,87] |
- Citation: Xue J, Niu J, Wu J, Wu ZH. MicroRNAs in cancer therapeutic response: Friend and foe. World J Clin Oncol 2014; 5(4): 730-743
- URL: https://www.wjgnet.com/2218-4333/full/v5/i4/730.htm
- DOI: https://dx.doi.org/10.5306/wjco.v5.i4.730